Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Active, not recruiting · NCT05407441 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, atypical teratoid rhabdoid tumor, chordoma, mixed neoplasm, neoplasm, rhabdoid tumor, rhabdoid tumor of the kidney, sarcoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT05407441 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Epizyme, Inc. | 8 |
| Susan Chi, MD | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital | Boston | United States | 343 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Texas Children's Hospital | Houston | United States | 187 |